German healthcare investor SHS Capital acquires majority stake in CAM Bioceramics

German healthcare investor SHS Capital acquires majority stake in CAM Bioceramics

Published: 07-07-2023 15:56:00 | By: Pie Kamau | hits: 3707 | Tags:

German healthcare specialist SHS Capital, together with ING Corporate Investments and other Co-Investors, is investing in CAM Bioceramics, a Leiden-based contract development and manufacturing organisation (CDMO) for innovative orthobiological calcium phosphate solutions.

Caspar Hogeboom, Shareholder and CEO, CAM Bioceramics: “We are delighted to have SHS and ING Corporate Investments on board, hence enabling CAM Bioceramics to serve our customers even better and to grow even faster. The existing Shareholders and the Management Team have consciously looked for the best partners to secure continuity and get access to additional and complementary business development opportunities. The partnership with SHS and ING is a validation of our strategy and capabilities and will fuel the company’s growth even further. The Management Team will remain fully intact and will continue to provide the best Customer Satisfaction possible to remain or to become your trusted partner for innovative calcium phosphate solutions and services worldwide.”

CAM Bioceramics was founded in 1985 as a spin-off from University Leiden Biomaterials Research Group and since than focused on developing orthobiological calcium phosphates (CaPs) materials in the field of medical technology and life sciences. Applications are amongst others orthobiological HA coating powder for orthopaedic, dental and spinal implants, bone graft substitutes, excipients and (CaPs) particles for injectable dermal fillers. As one of the leading companies in its field, CAM offers the unique combination of outstanding product and scientific know-how at the interface between chemistry, biology and material sciences combined with large scale production capacities to ensure constant supply and quality whilst remaining agile to provide continuous customer satisfaction.

SHS invested in the company together with ING Corporate Investments (a 100% subsidiary of the renowned Dutch ING Bank) as well as several Co-Investors. The existing owners rolled-over a significant stake in the company and will stay relevant shareholders of CAM Bioceramics securing the company`s Vision (“to be the trusted partner for innovative calcium phosphate solutions and services worldwide”), Mission and core values. Accordingly, the Management Team of the Company will also remain fully intact. The aim of the new partnership is to further strengthen the base of the company and to accelerate the human and monetary investments to further customer satisfaction beyond where it is today. Amongst others, CAM can now benefit from the many years of experience as well as the extensive network of SHS in the Healthcare sector what is expected to lead to additional collaboration and partnership opportunities, with existing and new customers.

Corstiaan Withagen, Managing Director, ING Corporate Investments: “CAM is a clear innovative market leader in the calcium phosphates healthcare niche delivering industry-leading quality at an unparalleled scale aiming and realizing the highest Customer Satisfaction possible. We are honoured to be part of CAM’s exciting journey and to team up with the German specialist healthcare investor SHS and are looking forward to work closely with CAM’s Management Team and SHS.”

Manfred Ulmer-Weber, Managing Partner, SHS: “SHS is very happy to be part of this exciting partnership and we look forward to continue working together with CAM and its Management Team and employees as well as with the existing Shareholders, ING and our Co-Investors. Based on the strong existing customer base and the outstanding capabilities of CAM, we are convinced that we can help to create additional collaboration opportunities and thus support the company in its further growth. The investment in CAM is already the third investment from our newly launched sixth fund generation and another opportunity to be involved in the establishment and further development of a European healthcare champion.”